# Case conference

Manisha Mehta, M.D

On Feb 26, 2008, a 63 year old white male was referred for

- Red and painful right eye with decreased vision
- Anterior uveitis not responding to topical steroids
- With increasing posterior synechial formation

# Past history:

- HLA-B27 positive recurrent anterior uveitis
   Affecting the right eye 2-3 times/ year
   Responding to steroids and cycloplegics
   for the past 10 years
- •Macular edema OD

# **Medical history:**

Psoriatic arthritis and skin lesions treated with narrow beam UV radiation

 Chronic lymphoid leukemia for one year on treatment with Rituxan and Fludarabine

# •Family history:

Father: Cancer

**Grandfather: Diabetes** 

**Aunt: Arthritis** 

#### •Medications:

IVIG (for treatment of peripheral neuropathy 2 years before CLL)

**Aspirin** 

# Review of systems:

**Fatigue** 

Poor appetite

Severe / recurrent nose bleeds

Skin rashes

Stiff joints


Painful or swollen joints

	OD	OS
Vision	20/50 cc	20/25 cc
IOP (mm of Hg)	15	12
Pupils	synechiae	
EOM	full	full
SLE:		
conjunctiva	Normal	normal
cornea	Diffuse keratic precipitates	Clear and compact
Anterior chamber	2.5+cells and flare	Deep and quiet
Iris	Posterior synechiae	normal
Lens	Hazy anterior capsule, cortical (1+) and nuclear sclerosis (2+)	Nuclear sclerosis (1+)
vitreous	Hazy view	normal
Fundus	Hazy view	normal

### **Management:**

#### Investigations:

OCT:



Foveal thickness

OD: 274

OS: 229

#### **Medications:**

Posterior synechiae broken with a 'dynamite cocktail '(adrenalin, atropine and cocaine) Transeptal Kenalog (40 mg) and IV Solumedrol (1 gm) Plan to start Humira (anti TNF alpha) after discussion with Oncologists

Enconopred Plus (Prednisolone Acetate 1%) q 1 hour OD Xibrom (Bromfenac Sodium) bid OD Homatropine tid-qid OD

Time line	Event	Management
March 14, 2008 (3 weeks later)	Tapering dose of Prednisolone acetate (q2h) Stopped Homatropine  -Flare up: Redness, Pain OD  -Vision: 20/ 50 OD  -IOP: 17 /14  +2 conjunctival injection  Keratic precipitates  AC: 2+cells +flare  Posterior synechiae	<ul> <li>Dose of Prednisolone acetate increased to q1h</li> <li>Restarted Homatropine tid OD</li> <li>Transeptal Kenalog 40 mg</li> <li>Continue Xibrom</li> </ul>

Time line	Event	Management
March 26, 2008 (3 weeks later)	Pain and Redness OD: 1 day Headaches Decreased vision OD  -Vision: LP OD 20/20 OS  -IOP: 60 OD 22 OS  -Cornea: stromal edema 1+ anterior synechiae  -AC: 2+ cell and flare	Emergent treatment:  50 cc of 25% Mannitol  500 mg Diamox  YAG iridotomy and AC paracentesis -22 mg Hg OD  Cytoxan infusion: dose 1 gm q 2 weekly  Cosopt (Timolol maleate/dorzolam)  Pred forte q2h OD
	-Iris: Iris bombe  -Fundus: OD: RPE mottling at macula Attenuated vessels	Homatropine q4 h OD  Xibrom bid OD

Time line	Event	Management
April 01, 2008 (1 week later)	No pain or redness Better vision  Vision: cc 20/50  -IOP: 11 /11  -Pupils: round and reactive  -AC: rare cell, well formed chamber  -Iris: Posterior synechiae at 11 o'clock  -Fundus: OD: Vitreous strands Pale OD RPE mottling at macula Attenuated vessels  WBC: 6.2 k/ul	Pred forte tapered to 6 times/day  Cosopt continued  Xibrom continued

Time line	Event	Management
May 07, 2008 (5 weeks later)	Trouble with nocturnal vision with oncoming lights while driving  Vision: cc 20/40 OD  IOP: 14/14  Pupils: round and reactive  AC: deep and quiet  Lens: nuclear sclerosis and posterior subcapsular cataract OD  WBC: 4.3 k/ul	Cytoxan withheld Pred forte bid Xibrom continued

Time line	Event	Management
May 15, 2008 (1 week later)	Fatigue Vision: 20/40 cc AC: PI open, posterior synechiae IOP: 14 WBC: 5.6 k/ul	Cytoxan resumed at lower dose 750 mg  Pred forte qd  Cosopt bid
May 30, 2008 (2 weeks later)	Fatigue and tiredness  Vision: 20/30 AC: 1+ flare WBC: 2.9 k/ul	Cytoxan withheld  Solumedrol infusion +
June 05, 2008 (1 week later)	No new redness or pain  Vision: cc 20/30 IOP 16/14  WBC: 5.0 k/ul	Cytoxan (750 mg, q 2 weekly) Solumedrol Pred forte qd Xibrom Cosopt

Tim	ne line	Event	Management
	7, 2008 month later)	CE/IOL OD	Cytoxan reduced to 500 mg (every 3 weekly)  Solumedrol 1 gm  Xibrom  Cosopt
	g 07, 2008 nonth later)	Increasing fatigue  Advised to decrease Cytoxan by Oncologist	Cytoxan changed to Methotrexate 15 mg/week  Xibrom  Cosopt  Pred forte qd OD
200	months	Vision: cc 20/20 IOP: 8/9 AC: deep and quiet	Methotrexate 15 mg/week  Cosopt  Xibrom

Time line	Event	Management
January, 2009	Restarted chemotherapy for CLL with Rituxan, Fludarabine and Cytoxan	Stopped MTX Xibrom continued Cosopt continued
Feb 03, 2009	OCT:  Foveal thickness OD 248 OS 215 IOP: 8/10 OD quiet	Xibrom Cosopt
April 28, 2009	Follow up Vision: cc 20/20 IOP: 12/10 OD quiet	Xibrom reduced to qd  Cosopt
July 28, 2009	Follow up Vision cc 20/20 IOP 12/11 OD quiet	Xibrom qd  Cosopt bid

# **HLA-B27 syndromes**

- •HLA molecules are genetically encoded by the major histocompatibility complex (MHC) found on chromosome 6
- •Role in immunity and in self-recognition in all nucleated cells and tissues
- •Mechanisms of HLA-B27 associated inflammatory response:
- -Molecular mimicry
- -Arthritogenic peptide
- -Innate etiology unrelated to HLA
- -Marker closely linked to unidentified true immune gene responsible for inflammatory response.

# **HLA-B27** associated Acute Anterior Uveitis:

•Male predominance

•Age: 20- 40 yrs

Associated with seronegative arthritic syndromes

- -Ankylosing spondylitis
- -Reactive arthritis
- -Psoriatic arthritis
- -Inflammatory bowel disease

# **Ankylosing Spondylitis**

Chronic progressive disease with 88% cases positive for HLA-B27


Chance of eye disease: 1:4

Young males, 3<sup>rd</sup> decade

Sacroiliac joints: lower back pain and stiffness after inactivity

Other systems involved: lungs (pulmonary apical fibrosis)

heart (aortitis and aortic insufficiency)



# Reactive Arthritis (Reiter syndrome)

- •18-40 years
- Acute nonpurulent arthritis secondary to an infection elsewhere
- •Enteric (diarrhoea) or urogenital infections (dysuria) in HLA-B27 positive individuals
- •60-85% individuals with reactive arthritis are HLA-B27 positive
- Organisms:

Shigella flexneri, Salmonella species, Yersinia enterocolitica, Campylobacter jejuni, Chlamydia trachomatis, Chlamydia pneumoniae, Clostridium difficile, Ureaplasma urealyticum

# **Reactive Arthritis**

- Non specific urethritis,
- Conjunctivitis (mucopurulent and papillary)
- Arthritis (knees, ankles, feet, wrists)

Minor diagnostic criteria: plantar fasciitis, Achilles tendonitis, nail bed pitting, palate ulcers and tongue ulcers

Major diagnostic criteria: keratoderma blennorrhagicum, circinate balanitis





# Inflammatory bowel disease

- •Ulcerative colitis (5-12%) and Crohn disease (2.4%) are associated with AAU
- •50-60% cases with spondylitis in association with inflammatory bowel disease are positive for HLA-B27
- Small bony erosions and joint space narrowing
- Ankylosing spondylitis

## **Psoriatic Arthritis**

- •HLA-B27 is associated with the pustular form of psoriasis
- •60-70% of cases with spondylitis associated psoriasis are HLA-B27 positive
- •3-4 th decade
- •Mild intermittent arthritis (sausage shaped digits) except arthritis mutilans
- Psoriatic skin lesions: look like eczema and seborrheic dermatitis

## **HLA-B27** associated Acute anterior uveitis

- Non granulomatous unilateral disease (pain, redness, photophobia)
- Corneal: fine KP, fibrin on endothelium, corneal edema, band keratopathy
- •AC: fibrinous exudate in AC, cells and flare, iris bombe, hypopyon


Rare posterior segment involvement




•Cystoid macular edema, disc edema, pars plana exudates, choroiditis

## **HLA-B27** associated Acute anterior uveitis

- Tendency to recur
- •Complications: cataract, glaucoma, hypotony, CME, synechiae formation





Poorer prognosis than HLA-B27 negative AAU

#### **Treatment**

- •Steroids: Topical, periocular, intravitreal and oral
- Cycloplegics
- •Immunosuppressive therapy:
- refractory cases
- steroid induced adverse effects, steroid dependant cases
- vision threatening inflammation
- -Azathioprine, Cyclophosphamide, Chlorambucil, Methotrexate, Cyclosporin
- •Immunomodulation therapy: Infliximab (antiTNF-alpha), Etanercept (antiTNF alpha and beta)
- Sulfasalazine (in reactive arthritis)
- HLA-B27 derived peptide (B27PD) oral tolerance therapy
- Rheumatology consult

Thank you.....